CTPS1 Inhibitors

Step Pharma’s most advanced candidate is STP938, a small molecule inhibitor of CTPS1 currently in non-clinical development. CTPS1 is specifically highly expressed in activated T and B cells. STP938 has shown anti-proliferative and cytotoxic effects against a range of cancers in in vitro tumour models. STP938 has also shown in vivo effects in models of autoimmunity.

STP938 will enter clinical development in 2021 for the treatment of certain blood cancers.

CTPS1 mRNA expression levels in blood cell lineage
Share this page